We performed this multiplex cytokine assay and the qualification of the immunoassay for suitability for its intended purpose using Meso Scale Discovery to simultaneously quantify eight (8) inflammatory biomarkers: multiplex IL-1 beta/IL-1F2, IL-2, IL-6, IL-8/CXCL8, IL-10, IFN-alpha-2a, IFN-gamma, and TNF-alpha in human plasma.
Each step of this MSD ECL multiplex assay for cytokine quantification must be optimized to improve reproducibility and robustness.
Solution
One of our clients wanted to determine the inflammatory status of subjects in a clinical trial following administration of their drug. To this end, we recommended an eight (8)-plex pro-inflammatory V-PLEX cytokine/chemokine panel based on Meso Scale Discovery.
This MSD-platform-based cytokine assay uses antibody cocktails for the eight analytes in a 96-well plate format to deliver a reproducible assay with high sensitivity and specificity for these biomarkers. Thanks to the Meso Scale Discovery platform’s multiplexing capabilities for inflammatory biomarkers, multiple cytokines can be quantified simultaneously from a single sample, providing comprehensive insights into immune responses and inflammatory status. This approach is crucial in cytokine quantification assays, where assessing various inflammatory markers provides a holistic understanding of the dynamics of the immune system and the effectiveness of treatment.
The Meso Scale Discovery platform offers bioanalysis with improved sensitivity, minimal matrix effects, and a wider dynamic range, enabling the measurement of multiple analytes from a single sample (i.e., multiplexing). This capability is particularly valuable in cytokine assays. Furthermore, the MSD ECL platform offers stability and is non-radioactive thanks to easily conjugated labels. These advantages make MSD a robust alternative to conventional colorimetric methods such as ELISA for the quantification of cytokines.
Here, we coated the MSD multi-array cytokine test plate with a cocktail of capture antibodies for one hour at room temperature (RT), enabling the detection of multiplexes of inflammatory biomarkers. We then prepared standard curves, quality controls, and samples in accordance with FDA regulatory requirements for the validation of bioanalytical methods and sample analysis. Next, 1% BSA blocker, standards, quality controls, and samples were added to the coated plate and incubated at room temperature on a shaker. We then washed away excess or unbound proteins in automated plate washers. For detection, our team added SULFO-TAG-conjugated antibody and captured the ECL signal on an MSD imager.
Results
We have developed and qualified a reliable mesoscale multiplex cytokine assay for the detection and quantification of chemokines and cytokines, which serves as a valuable multiplex for inflammatory biomarkers. This cytokine assay has been carefully validated and continues to support multiple projects focused on assessing inflammatory status.
Biomarker measurements are becoming increasingly important for understanding disease progression and the development of therapies. Cytokine assays are an integral part of this process, as cytokines are key mediators of inflammation and immune responses. The quantification of cytokines provides us with valuable insights into disease progression and therapeutic efficacy. This underscores the importance of robust cytokine assays for enhancing our understanding of various diseases and guiding the development of targeted therapies.
The traditional ELISA platform has long been valued for its effectiveness in quantifying a single analyte. However, the emerging MSD platform represents a significant advancement in the field of cytokine assays. Thanks to its ability to analyze multiple biomarkers simultaneously, the MSD platform is revolutionizing cytokine quantification assays. This innovative technology offers unmatched accuracy and precision, even in complex biological matrices. By harnessing the power of the MSD platform, researchers can perform comprehensive cytokine quantification using minimal sample volumes. This capability enhances the efficiency of cytokine quantification studies and opens new avenues for understanding immune responses and inflammatory processes.
Registered and approved by various regulatory agencies
Talk to our scientist about your multiplex cytokine assay and cytokine quantification at Meso Scale Discovery
Related articles
TaqMan Gene Expression Assay, Copy Number Variation Assay Development, nGLP Validation, And Sample Analysis
Genomic Variation Analysis – TaqMan Single Nucleotide Polymorphism (SNP) Analysis
LC MS Bioanalysis Of Antisense Oligonucleotide (ASO) Using Mass Spectrometry And Ion Pair Chromatography
Epigallocatechin Gallate (EGCG) LC MS Method Development, GLP Validation, And Sample Analysis In VcEDTA Human Serum
LC MS Method For Proline Amino Acid, Hydroxyproline In Mouse Tissues
LC MS Method For DNA Adducts Analysis In Cell-Based In-Vitro Samples
LC MS Method for Everolimus Eluting Coronary Stent Drug Delivery Systems
Mass Spectrometry Amino Acids, Quantitative LC MS Amino Acid Analysis
LC MS Method Development And GLP Validation For Human Plasma PK Sample Analysis
Incurred Sample Reanalysis (ISR) Test, FDA Requirements, And Study Evaluation
Dried Blood Spot (DBS) Sampling, DBS Collection, And DBS Analysis
Your partner in quality, safety, and compliance
The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.